By Fineline Cube 
Sisram Medical Ltd (HKG: 1696), an Israel-based aesthetic medical technology company and subsidiary of Fosun Pharmaceutical Group, announced a strategic partnership with U.S.-based Revance Therapeutics, Inc. and Shanghai Fosun Pharmaceutical Development Co., Ltd. The collaboration focuses on establishing a comprehensive long-term strategic framework and key commercial terms for Daxxify, the world’s first long-acting botulinum toxin type A product utilizing proprietary peptide exchange technology.
Partnership Framework
| Item | Detail |
|---|---|
| Lead Company | Sisram Medical Ltd (HKG: 1696) |
| Partners | Revance Therapeutics, Inc. & Shanghai Fosun Pharmaceutical Development Co., Ltd. |
| Product | Daxxify (long-acting botulinum toxin type A) |
| Technology | Proprietary peptide exchange technology |
| Commercial Launch | January 2026 in China |
| Partnership Focus | Long-term strategic framework and key commercial terms |
Product Innovation & Market Positioning
Technological Differentiation
- First-in-Class: World’s first long-acting botulinum toxin type A
- Proprietary Platform: Peptide exchange technology enabling extended duration
- Market Gap: Addresses demand for longer-lasting aesthetic treatments with reduced retreatment frequency
Commercial Advantages
- Duration Profile: Significantly extended effect duration compared to conventional botulinum toxins
- Patient Appeal: Reduced treatment frequency enhances convenience and compliance
- Provider Benefits: Streamlined scheduling and improved patient retention
Strategic Resource Integration
Fosun Pharmaceutical Development Strengths
- Industry Chain Integration: Deep resource accumulation across entire pharmaceutical value chain
- Industrial Influence: Established market presence and regulatory expertise in China
- Commercial Infrastructure: Comprehensive distribution and marketing capabilities
Revance Therapeutics Expertise
- Technological Leadership: Cutting-edge expertise in injectable filler technologies
- R&D Capabilities: Core product development advantages in aesthetic therapeutics
- Innovation Pipeline: Proprietary platform technologies beyond Daxxify
Sisram Medical Contribution
- Global Channel Deployment: International distribution network and market access
- Operational Excellence: Refined operational strengths in aesthetic medical device commercialization
- Cross-Border Coordination: Bridge between Western innovation and Chinese market execution
Market Acceleration Strategy
The tripartite alliance aims to comprehensively accelerate Daxxify’s commercialization in China through:
- Leveraging Fosun’s established healthcare ecosystem
- Utilizing Revance’s technological and regulatory expertise
- Deploying Sisram’s global channel optimization capabilities
- Implementing refined operational strategies for rapid market penetration
China represents one of the world’s fastest-growing aesthetic markets, with botulinum toxin treatments experiencing double-digit annual growth. Daxxify’s unique long-acting profile positions it to capture premium market segments seeking enhanced convenience and efficacy.
Forward‑Looking Statements
This brief contains forward-looking statements regarding strategic partnerships, commercial timelines, and market positioning. Actual commercial outcomes, market share capture, and revenue generation may differ based on competitive dynamics, regulatory considerations, and market adoption rates.-Fineline Info & Tech